 WESTLAKE VILLAGE, Calif., Aug. 01, 2022 GLOBE NEWSWIRE -- Arcutis Biotherapeutics, Inc. Nasdaq: ARQT, an early-stage commercial biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, will host a conference call for investors today at 8:30 a.m. EDT to discuss the U.S. Food and Drug Administration FDA approval of ZORYVE roflumilast cream 0.3 for treatment of plaque psoriasis, including intertriginous areas, in patients 12 years of age and older. 